Lisa M. Rimsza

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy

Mazyar Shadman, Michael LeBlanc, Lisa M. Rimsza, John Paul Leonard et autres

Importance: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. Objective: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with …

us (code pays fourni par la source)

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

Daniel Filip, Katerina Musilova Litzmanova, Androniki Michaelou, Filip Kledus et autres

Follicular lymphoma (FL) patients are at risk of disease transformation to aggressive high-grade lymphoma (tFL). While several genetic alterations have been implicated in tFL, the role of microenvironmental interactions and post-transcriptional regulation by non-coding RNAs remains poorly understood. We performed the first …

cz, at, us, de (code pays fourni par la source)

Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy

Hervé Ghesquières, Youenn Drouet, Susan L. Slager, Franck Morschhauser et autres

Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as well as failure within the first 24 months after treatment …

fr, us, it, in (code pays fourni par la source)

Investigating polyclonal Follicular Lymphoma tumors to determine the inciting factors for lymphomagenesis 4549

Miranda S. Siminski, Jordan Edward Krull, Abigail R. Dropik, Janek S. Walker et autres

Abstract Description Follicular Lymphoma (FL) is a germinal center-derived malignancy representing approximately 20% of all non-Hodgkin’s lymphomas. Despite a relatively indolent disease course, FL is a biologically and clinically heterogeneous disease which poses significant clinical challenges due to its propensity for relapse …

us (code pays fourni par la source)

Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma

Colleen A. Ramsower, George W. Wright, Hongli Li, James R. Cerhan et autres

ABSTRACT: Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based on a 45-target gene expression profiling …

us, Afrique du Sud, ca (code pays fourni par la source)

Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study

Michael Superdock, Lisa M. Rimsza, Danielle S. Wallace, Myla Strawderman et autres

Primary mediastinal large B-cell lymphoma (PMBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) that accounts for 2–4% of NHL cases [1,2]. It most commonly presents as a locally invasive anterior...

us (code pays fourni par la source)

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Katja Gutmair, Diego R. Villa, Nicholas Cunningham, Elisabeth Silkenstedt et autres

Rituximab and bendamustine (BR) is a standard first-line regimen in older patients with mantle cell lymphoma (MCL) based on the StiL-1 and BRIGHT trials.1,2 Maintenance rituximab (MR) is commonly used as part of first-line therapy, based on randomized studies showing an overall …

nl, de, ca, gb, us (code pays fourni par la source)

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Joseph Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan et autres

Background: Mantle cell lymphoma (MCL) is incurable with standard chemotherapy. Although oral targeted agents are active in MCL, they fail to induce deep responses as monotherapy and are administered chronically. We developed a fixed-duration, multi-agent targeted regimen (ViPOR) and showed it to …

us (code pays fourni par la source)

Data from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

Amit Dipak Amin, Soumya Sundara Rajan, Winnie S. Liang, Praechompoo Pongtornpipat et autres

Abstract The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain cancers, including 2% to 7% of non–small cell lung cancers (NSCLC) and ∼70% of anaplastic large cell lymphomas (ALCL). The ALK kinase inhibitors crizotinib and ceritinib are approved …

Supplementary Figure Legend from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

Amit Dipak Amin, Soumya Sundara Rajan, Winnie S. Liang, Praechompoo Pongtornpipat et autres

Supplementary Figure Legend. Legend for Supplementary Figures S1-S5.

Data from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

Amit Dipak Amin, Soumya Sundara Rajan, Winnie S. Liang, Praechompoo Pongtornpipat et autres

Abstract The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain cancers, including 2% to 7% of non–small cell lung cancers (NSCLC) and ∼70% of anaplastic large cell lymphomas (ALCL). The ALK kinase inhibitors crizotinib and ceritinib are approved …

Supplementary References from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

Amit Dipak Amin, Soumya Sundara Rajan, Winnie S. Liang, Praechompoo Pongtornpipat et autres

Supplementary References